Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has been featured in a BioMedWire editorial examining emerging approaches to treating multiple sclerosis (MS), a disease that affects more than 2.9 million people globally. The editorial highlights the company’s patented Lucid-MS drug candidate, a first-in-class therapy designed to protect the myelin sheath targeted by MS. According to the press release, the program is preparing to enter Phase 2 clinical trials as Quantum pursues a novel strategy aimed at addressing a significant unmet need in the treatment of the disease.
The importance of this development lies in the potential of Lucid-MS to change the treatment landscape for MS. Current therapies primarily focus on managing symptoms or modulating the immune system, but Lucid-MS is designed to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. In preclinical models, the drug has shown the ability to prevent and reverse myelin degradation, which could translate into a disease-modifying therapy for patients. For the 2.9 million individuals living with MS worldwide, a therapy that directly targets the root cause of the disease could significantly improve quality of life and slow disease progression.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS. The company’s pipeline also includes UNBUZZD, a product for alcohol misuse, which has been spun out into Unbuzzd Wellness Inc. Quantum retains a 19.84% ownership stake in Unbuzzd as of March 31, 2026, along with royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
The editorial in BioMedWire, a specialized communications platform focused on the biotechnology and life sciences sectors, underscores the potential market impact of Lucid-MS. With MS affecting a significant portion of the global population, there is a substantial unmet need for therapies that can halt or reverse disease progression. If successful in Phase 2 trials, Lucid-MS could become a cornerstone treatment for MS, offering hope to millions of patients and generating significant revenue for Quantum. Investors and industry observers are closely watching the progress of this program, as positive results could position Quantum as a leader in neurodegenerative disease treatment.
For more information on Quantum BioPharma, visit the company’s newsroom at https://ibn.fm/QNTM. The full press release detailing this announcement is available at https://ibn.fm/KdvrI.
